Unpartnered Products: Partnerships that could be Game Changers
Unpartnered products represent a potential multi-billion dollar opportunity.
There are opportunities for companies of all sizes:
• Large pharma & smaller cash-rich pharma companies
Can use a partnership with an unpartnered drug to enter new therapy areas or strengthen their existing pipelines.
• Big pharma
Has opportunities to off-load their existing assets that aren’t critical to their growth strategy or that would be a better fit for other companies willing to pay a premium.
• Cash-rich big pharma
Has opportunities to replenish potentially depleting pipelines by acquiring smaller biotech/pharmaceutical companies, or co-developing drugs that have not been partnered.
1 - Unpartnered Products by Therapy Area & Phase
2 - Unpartnered Products – Listing by Therapy Area
3 - Top 5 North American Private Companies with Unpartnered Products
4 - North America Public Companies with Less Than One Year Cash Remaining – Key TA’s
5 - Top 5 North American Public Companies – Less Than One Year Cash
6 - LICENSING DEALS BY THERAPEUTIC AREA
Oncology deals were greatest in number in 2013 , followed by Diagnostics and Central Nervous System deals.
7 - PARTERSHIP DEALS: Volume Distribution across Therapy Areas::See Chart::
8 - PARTNERSHIP DEALS ANALYSIS BY PHASE
The average total implied deal value varied by phase, with Research deals demanding the greatest cumulative total value at $15.2 bn , followed by those deals involving Phase II assets with $5.8 bn.
9 - ROYALTIES ANALYSIS BY PHASE AND THERAPEUTIC AREA
Candidates further along in development receive higher royalty rates to compensate licencors for the costs and development time already committed and to account for their greater likelihood of approval.
10 - Some Therapy Areas (TA) demand greater royalty rates than others.